Señalización JAK / STAT
Los inhibidores de la señalización JAK/STAT son compuestos que interrumpen la vía de la cinasa Janus (JAK) y del transductor y activador de la transcripción (STAT), la cual está involucrada en la señalización de citoquinas, el crecimiento celular y la respuesta inmunitaria. Estos inhibidores son herramientas importantes para estudiar la regulación de esta vía y su papel en diversas enfermedades, como el cáncer, los trastornos inmunitarios y las condiciones inflamatorias. Los inhibidores de JAK/STAT también están siendo desarrollados como terapias dirigidas para estas enfermedades. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de la señalización JAK/STAT para apoyar su investigación en biología molecular, oncología e inmunología.
Subcategorías de "Señalización JAK / STAT"
Se han encontrado 321 productos de "Señalización JAK / STAT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BP-5-087
CAS:<p>BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.</p>Fórmula:C36H30F8N2O6SForma y color:SolidPeso molecular:770.69Galiellalactone
CAS:<p>inhibits IL-6-mediated JAK/STAT signal transduction</p>Fórmula:C11H14O3Pureza:98%Forma y color:SolidPeso molecular:194.23CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Forma y color:SolidPeso molecular:303.36GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Fórmula:C21H18ClF2N7O3Forma y color:SolidPeso molecular:489.86Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Fórmula:C18H23BrN4O2Forma y color:SolidPeso molecular:407.312Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Fórmula:C23H22F5N7OForma y color:SolidPeso molecular:507.469(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OForma y color:SolidPeso molecular:285.34YM-341619
CAS:<p>YM-341619 (AS1617612), potent STAT6 inhibitor; IC50: 0.70 nM; hinders IL-4-induced Th2 in mice; may aid allergic disease research.</p>Fórmula:C22H21F3N6O2Forma y color:SolidPeso molecular:458.44TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Fórmula:C22H25F2N5O2Forma y color:SolidPeso molecular:429.46Stafia-1-dipivaloyloxymethyl ester
CAS:<p>Stafia-1 suppresses pSTAT5a in a dose-dependent manner (0-200 μM) without affecting pSTAT5b.</p>Fórmula:C37H48FO13PForma y color:SolidPeso molecular:750.74MM-206
CAS:<p>MM-206, a cell-permeable, non-cytotoxic naphthalene sulfonamide compound, it effectively inhibits STAT3 DNA-binding activity.</p>Fórmula:C22H12F5NO3S2Forma y color:SolidPeso molecular:497.46MC0704
<p>MC0704: STAT3 inhibitor, IC50=2.13μM, promotes apoptosis & cell arrest, anti-breast cancer, for mTNBC research.</p>Fórmula:C29H21BrN4O2Forma y color:SolidPeso molecular:537.41STAT3-IN-15
<p>STAT3-IN-15: Potent, oral STAT3 inhibitor for IPF, blocks STAT3 phosphorylation, cell migration, and EMT.</p>Fórmula:C20H17F3N2O3SForma y color:SolidPeso molecular:422.42Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Fórmula:C28H28ClN5O4SForma y color:SolidPeso molecular:566.07HJC0149
CAS:<p>HJC0149 is a potent orally bioavailable signal transducer and activator of transcription 3 inhibitor.</p>Fórmula:C15H10ClNO4SForma y color:SolidPeso molecular:335.76TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SForma y color:SolidPeso molecular:383.42SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Fórmula:C24H26N8O3Forma y color:SolidPeso molecular:474.52PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OForma y color:SolidPeso molecular:342.44LLL12
CAS:<p>LLL12 inhibits STAT3 phosphorylation, boosting Cisplatin and Paclitaxel effects against ovarian cancer cell activities.</p>Fórmula:C14H9NO5SForma y color:SolidPeso molecular:303.29JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Fórmula:C20H18FN5O3SPureza:99.53%Forma y color:SolidPeso molecular:427.45JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Fórmula:C26H30ClN7O2Forma y color:SolidPeso molecular:508.02JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Fórmula:C25H28N8OPureza:97.89%Forma y color:SolidPeso molecular:456.54JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Fórmula:C19H26N8SPureza:98%Forma y color:SolidPeso molecular:398.53JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Fórmula:C20H18ClN7OPureza:98%Forma y color:SolidPeso molecular:407.86AZD-1897
CAS:<p>AZD-1897 is a highly efficient ATP-competitive pan-PIM inhibitor with anti-cancer and anti-leukemia activity, used in multiple myeloma research.</p>Fórmula:C18H23N3O3SPureza:99.49%Forma y color:SolidPeso molecular:361.46M-110
CAS:<p>M-110 selectively targets PIM kinases, best at PIM-3 (IC50=47nM), and inhibits prostate cancer cell growth (IC50=0.6-0.9μM).</p>Fórmula:C22H28ClN5O3Pureza:99.55%Forma y color:SolidPeso molecular:445.94JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Fórmula:C26H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Fórmula:C25H32N8O2Pureza:99.64% - 99.87%Forma y color:SolidPeso molecular:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Fórmula:C18H15FN4O3Pureza:98.61% - 99.81%Forma y color:SolidPeso molecular:354.34Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Fórmula:C12H12N4O5Forma y color:SolidPeso molecular:292.25PIM-1 Inhibitor 2
CAS:<p>PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.</p>Fórmula:C17H11ClN4OPureza:98.81%Forma y color:SolidPeso molecular:322.75JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Fórmula:C22H23FN4O3SPureza:98.4%Forma y color:SolidPeso molecular:442.51STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Forma y color:SolidPeso molecular:318.76Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Fórmula:C22H26N8Pureza:99.82%Forma y color:SolidPeso molecular:402.50JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Fórmula:C21H21N5O2Pureza:99.59%Forma y color:SolidPeso molecular:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Forma y color:SoildPeso molecular:591.55NT219
CAS:<p>NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3 that enhances the aggregation of misfolded prion proteins NT219 Effects.</p>Fórmula:C16H14BrNO5SPureza:98.06% - 99.72%Forma y color:SolidPeso molecular:412.26Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Fórmula:C18H21F2N7OPureza:99.82%Forma y color:SolidPeso molecular:389.4Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39PM-43I
CAS:<p>PM-43I is a potent inhibitor of both STAT5- and STAT6-dependent allergic airway disease in mice.</p>Fórmula:C38H50F2N3O10PForma y color:SolidPeso molecular:777.79JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Fórmula:C27H25F3N4O4Pureza:99.39% - ≥98%Forma y color:SolidPeso molecular:526.51STAT3-IN-14
CAS:<p>STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .</p>Fórmula:C14H10O5Forma y color:SolidPeso molecular:258.23Pim-1 kinase inhibitor 5
CAS:<p>Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-</p>Fórmula:C22H13Cl2N3OPureza:98%Forma y color:SolidPeso molecular:406.26JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Fórmula:C17H19F2N7OSPureza:98%Forma y color:SolidPeso molecular:407.44PIM1-IN-4
CAS:<p>PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.</p>Fórmula:C27H25BrCl2CuN6OPureza:98%Forma y color:SolidPeso molecular:663.88JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44GNE-955
CAS:<p>GNE-955 is a potent and orally active inhibitor of pan Pim kinase (Kis: 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively).</p>Fórmula:C22H24N8OPureza:98%Forma y color:SolidPeso molecular:416.48
